Status
Conditions
Treatments
About
The Purpose of this trial is to investigate the efficacy and safety of GGT on Korean obese Women with or without metabolic syndrome Risk factors
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Female aged 19 to 65 years
Subject must included at least one or more of the following symptoms below;
Agreed to low-calorie diet during the trial
Written informed consent of the trial
Exclusion criteria
Subjects who had experience with allergic reaction on investigational drug(any ingredients of IP)
Subjects who had 10 percent reduction in body weight over 6 months
Subjects who decided to quit smoking over the last 3 months or have irregular smoking habits
Subjects who have endocrine diseases associated with weight gain, such as hypothyroidism, Cushing's syndrome, etc.
Subjects who have heart disease (heart failure, angina pectoris, myocardial infarction)
Subjects who have uncontrolled hypertension despite the use of antihypertensive drugs (SBP > 145 mmHg or DBP > 95 mmHg)
Subjects who have uncontrolled diabetes despite the use of drugs (FBS>7.8 mmol/L (140 mg/dL))
Subjects who have severe renal disability (SCr > 2.0 mg/dL)
Subjects who have severe liver disability (2.5 fold of normal high range value on Alanine Aminotransferase [ALT], Aspartate Aminotransferase [AST], alkaline phosphatase [ALP])
Subjects who have poor digestion(anorexia, stomach discomfort, nausea, vomiting etc) or have the history of eating disorder such as anorexia nervosa or bulimia nervosa, etc.(KEAT-26 < 20)
Use of medication that can affect on weight within last 3 months (appetite suppressant, laxative, oral steroid, thyroid hormone, amphetamine, cyproheptadine, phenothiazine or medications can affect on absorption, metabolism, excretion)
Use of CNS stimulant medication for weight loss
Subjects who had a use of drugs that can increase blood pressure or heart rate within a week, such as, Decongestants, cough, cold, allergy treatments that include the ingredients of phenylpropanolamine, ephedrine, pseudoephedrine
Forbidden treatment (Insulin, hypoglycemic agent, antidepressant, antiserotonin agent, barbiturate, antipsychotic, medication concerns of abuse)
Subjects who have diseases that may occur hypokalemia (hypomagnesemia, Bartter syndrome, Gitelman syndrome, diseases that can cause high aldosteronism etc.) or have cardiac dysrhythmia
Difficult to measure anthropometric dimensions because of anatomical change such as resection
History of weight loss surgery, such as bariatric surgery, etc.
Edema or dysuria
Malignant tumour or lung disease
Cholelithiasis
History of narrow angle glaucoma
Subjects who have nervous or psychological medical history or presently suffer from the following diseases: depression, manic disorder, bipolar disorder, schizophrenia, epilepsy, alcoholism, anorexia, hyperphagia, etc.
Subjects who have history of stroke or temporary ischemic cardioplegia
Subjects who are judged to be inappropriate for the clinical study by the researchers
Women who were pregnant, lactating or have the chances of pregnancy who do not agree to proper contraception (birth-control pill, hormone implant, IUD, spermicide, condom, abstinence, etc.)
Use of other investigational product within last 1 month
Primary purpose
Allocation
Interventional model
Masking
140 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal